Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes : A subanalysis of theVERIFYstudy

Show full item record



Permalink

http://hdl.handle.net/10138/334016

Citation

Chan , J C N , Paldanius , P M , Mathieu , C , Stumvoll , M , Matthews , D R & Del Prato , S 2021 , ' Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes : A subanalysis of theVERIFYstudy ' , Diabetes, obesity and metabolism , vol. 23 , no. 1 , pp. 245-251 . https://doi.org/10.1111/dom.14192

Title: Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes : A subanalysis of theVERIFYstudy
Author: Chan, Juliana C. N.; Paldanius, Päivi M.; Mathieu, Chantal; Stumvoll, Michael; Matthews, David R.; Del Prato, Stefano
Contributor: University of Helsinki, HUS Children and Adolescents
Date: 2021-01
Language: eng
Number of pages: 7
Belongs to series: Diabetes, obesity and metabolism
ISSN: 1462-8902
URI: http://hdl.handle.net/10138/334016
Abstract: We analysed glycaemic durability (sustained glycaemic control) with early combination therapy (metformin plus vildagliptin) versus metformin monotherapy, among patients with type 2 diabetes diagnosed before (young-onset [YOD]) and after (late-onset [LOD]) the age of 40 years, enrolled in the VERIFY trial. The primary endpoint was time to initial treatment failure (TF), defined as HbA1c of 7.0% or higher at two consecutive scheduled visits after randomization. The time to secondary TF was assessed when both groups were receiving and failing on the combination. A total of 186 (9.3%) patients had YOD and 1815 (90.7%) had LOD with a mean age difference of 20.4 years. Compared with metformin monotherapy, early combination reduced the risk of time to initial TF for both YOD (48%,P<.0006) and LOD (46%,P<.0001). With early combination, risk for time to secondary TF was reduced by 48% (P<.0035) in YOD and 24% (P<.0009) in LOD. Both treatment approaches were well tolerated with no unexpected safety concerns. In treatment-naive patients with YOD (HbA1c 6.5%-7.5%), an early combination strategy improved attainment of the glycaemic target with durability and delayed treatment escalation compared with initial metformin monotherapy.
Subject: glycaemic control
metformin
randomized trial
vildagliptin
FAILURE
ASIA
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
VERIFY_YOD_revi ... 2nd_resubmission_draft.pdf 374.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record